1. |
Loibl S, Gianni L. HER2-positive breast cancer. Lancet, 2017, 389(10087): 2415-2429.
|
2. |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版). 中国癌症杂志, 2021, 31(10): 954-1040.
|
3. |
Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ⅰb study. J Clin Oncol, 2020, 38(17): 1887-1896.
|
4. |
Xu Z, Guo D, Jiang Z, et al. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan (DS-8201a) and (Vic-) trastuzumab duocarmazine (SYD985). Eur J Med Chem, 2019, 183: 111682. doi: 10.1016/j.ejmech.2019.111682.
|
5. |
Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights breast cancer, version 1. 2016. J Natl Compr Canc Netw, 2015, 13(12): 1475-1485.
|
6. |
Jiao DC, Zhu JJ, Qin L, et al. Clinical practice guidelines for modified radical mastectomy of breast cancer: Chinese Society of Breast Surgery (CSBrs) practice guidelines 2021. Chin Med J (Engl), 2021, 134(8): 895-897.
|
7. |
Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol, 2018, 25(7): 1783-1785.
|
8. |
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. Ⅰ. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 1991, 19(5): 403-410.
|
9. |
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol, 2013, 31(31): 3997-4013.
|
10. |
Fitzgibbons PL, Dillon DA, Alsabeh R, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med, 2014, 138(5): 595-601.
|
11. |
Pondé N, Brandão M, El-Hachem G, et al. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev, 2018, 67: 10-20.
|
12. |
Andersson M, Lidbrink E, Bjerre K, et al. Phase Ⅲ randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol, 2011, 29(3): 264-271.
|
13. |
Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol, 2016, 2(12): 1557-1564.
|
14. |
Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol, 2018, 36(20): 2105-2122.
|
15. |
Onsum MD, Geretti E, Paragas V, et al. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. Am J Pathol, 2013, 183(5): 1446-1460.
|
16. |
Fehrenbacher L, Cecchini RS, Geyer CE, et al. NSABP B-47/NRG oncology phase Ⅲ randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol, 2020, 38(5): 444-453.
|
17. |
Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol, 2020, 38(17): 1951-1962.
|
18. |
Rossi V, Sarotto I, Maggiorotto F, et al. Moderate immunohisto-chemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. Oncologist, 2012, 17(11): 1418-1425.
|
19. |
Shui R, Liang X, Li X, et al. Hormone receptor and human epidermal growth factor receptor 2 detection in invasive breast carcinoma: a retrospective study of 12 467 patients from 19 Chinese representative clinical centers. Clin Breast Cancer, 2020, 20(1): e65-e74. doi: 10.1016/j.clbc.2019.07.013.
|
20. |
Zhang G, Ren C, Li C, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med, 2022, 20(1): 142. doi: 10.1186/s12916-022-02346-9.
|
21. |
Tarantino P, Jin Q, Tayob N, et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol, 2022, 8(8): 1177-1183.
|
22. |
Xin L, Wu Q, Zhan C, et al. Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021). Chin Med J (Engl), 2022, 135(6): 697-706.
|
23. |
Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer, 2021, 7(1): 1. doi: 10.1038/s41523-020-00208-2.
|
24. |
Di Fiore PP, Pierce JH, Kraus MH, et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science, 1987, 237(4811): 178-182.
|
25. |
Choong GM, Cullen GD, O’Sullivan CC. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin, 2020, 70(5): 355-374.
|
26. |
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235(4785): 177-182.
|
27. |
Mutai R, Barkan T, Moore A, et al. Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. Breast, 2021, 60: 62-69.
|
28. |
Li Y, Abudureheiyimu N, Mo H, et al. In real life, low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer: a study of the National Cancer Center, China. Front Oncol, 2022, 11: 774577. doi: 10.3389/fonc.2021.774577.
|
29. |
Yu KD, Jiang YZ, Chen S, et al. Effect of large tumor size on cancer-specific mortality in node-negative breast cancer. Mayo Clin Proc, 2012, 87(12): 1171-1180.
|
30. |
Crowe JP Jr, Gordon NH, Shenk RR, et al. Primary tumor size. Relevance to breast cancer survival. Arch Surg, 1992, 127(8): 910-915.
|
31. |
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24 740 breast cancer cases. Cancer, 1989, 63(1): 181-187.
|
32. |
Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4): 207. doi: 10.1186/bcr2607.
|
33. |
Rakha EA, El-Sayed ME, Lee AH, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol, 2008, 26(19): 3153-3158.
|
34. |
Grann VR, Troxel AB, Zojwalla NJ, et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer, 2005, 103(11): 2241-2251.
|
35. |
Kwast AB, Voogd AC, Menke-Pluijmers MB, et al. Prognostic factors for survival in metastatic breast cancer by hormone receptor status. Breast Cancer Res Treat, 2014, 145(2): 503-511.
|
36. |
Kolarova I, Dusek L, Ryska A, et al. Impact of hormone receptor status on the behaviour of HER2+ breast cancer. In Vivo, 2020, 34(6): 3441-3449.
|